Assessing Stroke Risk in Patients With AF │Janssen Pharmaceuticals, Inc.

First Page		Document Content
Date: 2013-08-19 12:47:46 Aging-associated diseases Cardiac dysrhythmia Stroke Hematology CHADS2 score Management of atrial fibrillation Atrial fibrillation Thrombosis Embolism Circulatory system Medicine Health		Assessing Stroke Risk in Patients With AF │Janssen Pharmaceuticals, Inc. Add to Reading List Source URL: www.janssenpharmaceuticalsinc.com Download Document from Source Website File Size: 76,61 KB Share Document on Facebook

	CHADS2 Score H E R M ELINDA G. A B C E DE, M D H S A S S ISTA NT C L I N I CAL PRO F ES S OR UCI D E PA RTM ENT O F N E UROLOGY DocID: 1lgor - View Document
	Supplementary Material to Beyer-Westendorf et al. “Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry” (Thromb Haemost 2015; 113.6) DocID: 1gsBz - View Document
	DecemberAnti-Thrombotic Choices for Reducing Risk of Stroke in Atrial Fibrillation The “Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Preve DocID: 1gs4w - View Document
	NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Atrial Fibrillation DocID: 18nC9 - View Document
	PDF Document DocID: 17hZU - View Document